Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 AUD | +0.76% | -3.02% | -2.94% |
Apr. 30 | Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases | MT |
Apr. 24 | Germany's Evotec Appoints Permanent CEO | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 73.78 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Leisure & Recreation
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.94% | 1.24B | C | ||
+12.37% | 4.4B | D+ | ||
+24.84% | 2.13B | C | ||
-.--% | 1.93B | - | ||
-19.18% | 1.6B | C+ | ||
-7.87% | 1.43B | - | ||
-16.30% | 1.16B | - | ||
-8.72% | 1.14B | C- | ||
-.--% | 818M | - | - | |
-0.52% | 509M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings EVT Limited